300 research outputs found
Listeners integrate pitch and durational cues to prosodic structure in word categorization
In this study we investigate how listeners perceive vowel duration as a cue to voicing based on changes in pitch height, using a 2AFC task in which they categorized a target word from a vowel duration continuum as coat or code. We consider this issue in light of (1) psychoacoustic perceptual interactions between pitch and duration and (2) compensatory effects for prosodically driven patterning of pitch and duration in the accentual/prominence-marking system of English. In two experiments we found that listeners' interpretation of pitch as a psychoacoustic, or prosodic event is dependent on continuum step size and range. In Experiment 1 listeners exemplified the expected psychoacoustic pattern in categorization. In Experiment 2, we altered the duration continuum in an attempt to highlight pitch as a language-specific prosodic property and found that listeners do indeed compensate for prosodically driven patterning of pitch and duration. The results thus highlight flexibility in listeners' interpretation of these acoustic dimensions. We argue that, in the right circumstances, prosodic patterns influence listeners' interpretation of pitch and expectations about vowel duration in the perception of isolated words. Results are discussed in terms of more general implications for listeners' perception of prosodic and segmental cues, and possibilities for cross-linguistic extension
Recommended from our members
Flavonoid intake in European adults (18 to 64 years).
BACKGROUND: Flavonoids are a group of phenolic secondary plant metabolites that are ubiquitous in plant-based diets. Data from anthropological, observational and intervention studies have shown that many flavonoids are bioactive. For this reason, there is an increasing interest in investigating the potential health effects of these compounds. The translation of these findings into the context of the health of the general public requires detailed information on habitual dietary intake. However, only limited data are currently available for European populations. OBJECTIVE: The objective of this study is to determine the habitual intake and main sources of anthocyanidins, flavanols, flavanones, flavones, flavonols, proanthocyanidins, theaflavins and thearubigins in the European Union. DESIGN: We use food consumption data from the European Food Safety Authority (EFSA) and the FLAVIOLA Food Composition Database to estimate intake of flavonoids. RESULTS: Mean (Β±SEM) intake of total flavonoids in Europe was 428Β±49 mg/d, of which 136Β±14 mg/d were monomeric compounds. Gallated flavan-3-ols (53Β±12 mg/d) were the main contributor. The lowest flavonoid intake was observed in Mediterranean countries (monomeric compounds: 95Β±11 mg/d). The distribution of intake was skewed in many countries, especially in Germany (monomeric flavonoids; mean intake: 181 mg/d; median intake: 3 mg/d). CONCLUSIONS: The habitual intake of flavonoids in Europe is below the amounts found to have a significant health effect.This project was supported by the European Union (grant 226588, βFlaviolaβ). Mars, Inc., a member of the FLAVIOLA research consortium, provided support in the form of salaries for author HS, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.This is the final published version. It first appeared at http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0128132
Recommended from our members
Associations between flavan-3-ol intake and CVD risk in the Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk)
This is the final published version. It first appeared at http://www.sciencedirect.com/science/article/pii/S0891584915001173.Dietary intervention studies suggest that flavan-3-ol intake can improve vascular function and reduce the risk of cardiovascular diseases (CVD). However, results from prospective studies failed to show a consistent beneficial effect. Associations between flavan-3-ol intake and CVD risk in the Norfolk arm of the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) were investigated. Data were available from 24,885 (11,252 men; 13,633 women) participants, recruited between 1993 and 1997 into the EPIC-Norfolk study. Flavan-3-ol intake was assessed using 7-day food diaries and the FLAVIOLA Flavanol Food Composition database. Missing data for plasma cholesterol and vitamin C were imputed using multiple imputation. Associations between flavan-3-ol intake and blood pressure at baseline were determined using linear regression models. Associations with CVD risk were estimated using Cox regression analyses. Median intake of total flavan-3-ols was 1034mg/d (range: 0-8531mg/d) for men and 970mg/d (0-6695mg/d) for women, median intake of flavan-3-ol monomers was 233mg/d (0-3248mg/d) for men and 217 (0-2712mg/d) for women. There were no consistent associations between flavan-3-ol monomer intake and baseline systolic and diastolic blood pressure (BP). After 286,147 person-years of follow-up, there were 8463 cardiovascular events and 1987 CVD related deaths; no consistent association between flavan-3-ol intake and CVD risk (HR 0.93, 95% CI: 0.87; 1.00; Q1 vs Q5) or mortality was observed (HR 0.93, 95% CI: 0.84; 1.04). Flavan-3-ol intake in EPIC-Norfolk is not sufficient to achieve a statistically significant reduction in CVD risk.We thank all EPIC-Norfolk study participants and staff for their contribution to the study. We thank the members of the FLAVIOLA consortium for their critical review of the manuscript. The present study was supported by the EU (Grant 226588, βFlaviolaβ) and an unrestricted grant from Mars, Inc. Mars, Inc. had no role in the design and analysis of the study or in the writing of this article. EPIC-Norfolk is supported by Cancer Research UK (SP2024-0201 and SP2024-0204) and the Medical Research Council (G9502233). H.S. is employed by MARS, Inc., a member of the FLAVIOLA research consortium and a company engaged in flavanol research and flavanol-related commercial activities. None of the other authors has a conflict of interest to declare
Experimental Quantum Hamiltonian Learning
Efficiently characterising quantum systems, verifying operations of quantum
devices and validating underpinning physical models, are central challenges for
the development of quantum technologies and for our continued understanding of
foundational physics. Machine-learning enhanced by quantum simulators has been
proposed as a route to improve the computational cost of performing these
studies. Here we interface two different quantum systems through a classical
channel - a silicon-photonics quantum simulator and an electron spin in a
diamond nitrogen-vacancy centre - and use the former to learn the latter's
Hamiltonian via Bayesian inference. We learn the salient Hamiltonian parameter
with an uncertainty of approximately . Furthermore, an observed
saturation in the learning algorithm suggests deficiencies in the underlying
Hamiltonian model, which we exploit to further improve the model itself. We go
on to implement an interactive version of the protocol and experimentally show
its ability to characterise the operation of the quantum photonic device. This
work demonstrates powerful new quantum-enhanced techniques for investigating
foundational physical models and characterising quantum technologies
Infrared radiation from an extrasolar planet
A class of extrasolar giant planets - the so-called `hot Jupiters' - orbit
within 0.05 AU of their primary stars. These planets should be hot and so emit
detectable infrared radiation. The planet HD 209458b is an ideal candidate for
the detection and characterization of this infrared light because it is
eclipsed by the star. This planet has an anomalously large radius (1.35 times
that of Jupiter), which may be the result of ongoing tidal dissipation, but
this explanation requires a non-zero orbital eccentricity (~0.03), maintained
by interaction with a hypothetical second planet. Here we report detection of
infrared (24 micron) radiation from HD 209458b, by observing the decrement in
flux during secondary eclipse, when the planet passes behind the star. The
planet's 24 micron flux is 55 +/- 10 micro-Jy (1 sigma), with a brightness
temperature of 1130 +/- 150 Kelvins, confirming the predicted heating by
stellar irradiation. The secondary eclipse occurs at the midpoint between
transits of the planet in front of the star (to within +/- 7 min, 1 sigma),
which means that a dynamically significant orbital eccentricity is unlikely.Comment: to appear in Nature April 7, posted to Nature online March 23 (11
pages, 3 figures
Cost-Effectiveness of Peer-Delivered Interventions for Cocaine and Alcohol Abuse among Women: A Randomized Controlled Trial
<div><h3>Aims</h3><p>To determine whether the additional interventions to standard care are cost-effective in addressing cocaine and alcohol abuse at 4 months (4 M) and 12 months (12 M) from baseline.</p> <h3>Method</h3><p>We conducted a cost-effectiveness analysis of a randomized controlled trial with three arms: (1) NIDA's Standard intervention (SI); (2) SI plus a Well Woman Exam (WWE); and, (3) SI, WWE, plus four Educational Sessions (4ES).</p> <h3>Results</h3><p>To obtain an additional cocaine abstainer, WWE compared to SI cost 3,611 at 12 M. Per additional alcohol abstainer, WWE compared to SI cost 7,223 at 4 M and 12 M, respectively. At 12 M, 4ES was dominated (more costly and less effective) by WWE for abstinence outcomes.</p> <h3>Conclusions</h3><p>To our knowledge, this is the first cost-effectiveness analysis simultaneously examining cocaine and alcohol abuse in women. Depending on primary outcomes sought and priorities of policy makers, peer-delivered interventions can be a cost-effective way to address the needs of this growing, underserved population.</p> <h3>Trial Registration</h3><p>ClinicalTrials.gov <a href="http://www.clinicaltrials.gov/ct2/show/NCT01235091">NCT01235091</a></p> </div
A Randomized Controlled Trial of Chloroquine for the Treatment of Dengue in Vietnamese Adults
There is no available drug or vaccine against dengue, an acute viral disease that affects βΌ50 million people annually in tropical and sub-tropical countries. Chloroquine (CQ), a cheap and well-tolerated drug, inhibits the growth of dengue viruses in the laboratory with concentrations achievable in the body. To measure the antiviral efficacy of CQ in dengue, we conducted a study involving 307 adults with suspected dengue. Patients received a 3-day oral dosage of placebo or CQ early in their illness. Unfortunately, we did not see an effect of CQ on the duration of viral infection. We did, however, observe that CQ had a modest anti-fever effect. In patients treated with CQ, we observed a trend towards a lower incidence of dengue hemorrhagic fever, a severe form of dengue. We did not find any differences in the immune response that can explain this trend. We also found more adverse events, primarily vomiting, with CQ. This trial provides valuable new information on how to perform trials of antiviral drugs for dengue
Protocadherin-18 Is a Novel Differentiation Marker and an Inhibitory Signaling Receptor for CD8+ Effector Memory T Cells
CD8+ tumor infiltrating T cells (TIL) lack effector-phase functions due to defective proximal TCR-mediated signaling previously shown to result from inactivation of p56lck kinase. We identify a novel interacting partner for p56lck in nonlytic TIL, Protocadherin-18 (βpcdh18β), and show that pcdh18 is transcribed upon in vitro or in vivo activation of all CD8+ central memory T cells (CD44+CD62LhiCD127+) coincident with conversion into effector memory cells (CD44+CD62LloCD127+). Expression of pcdh18 in primary CD8+ effector cells induces the phenotype of nonlytic TIL: defective proximal TCR signaling, cytokine secretion, and cytolysis, and enhanced AICD. pcdh18 contains a motif (centered at Y842) shared with src kinases (QGQYQP) that is required for the inhibitory phenotype. Thus, pcdh18 is a novel activation marker of CD8+ memory T cells that can function as an inhibitory signaling receptor and restrict the effector phase
The size of the treatment effect: do patients and proxies agree?
Background: This study examined whether MS patients and proxy respondents agreed on change in disease impact, which was induced by treatment. This may be of interest in situations when patients suffer from limitations that interfere with reliable self-assessment, such as cognitive impairment.Methods: MS patients and proxies completed the Multiple Sclerosis Impact Scale (MSIS-29) before and after intravenous steroid treatment. Analyses focused on patient-proxy agreement between MSIS-29 change scores. Transition ratings were used to measure the patient's judgement of change and whether this change was reflected in the MSIS-29 change of patients and proxies. Receiver operating characteristic (ROC) analyses were also performed to examine the diagnostic properties of the MSIS-29 when completed by patients and proxies.Results: 42 patients and proxy respondents completed the MSIS-29 at baseline and follow-up. Patient-proxy differences between change scores on the physical and psychological MSIS-29 subscale were quite small, although large variability was found. The direction of mean change was in concordance with the transition ratings of the patients. Results of the ROC analyses of the MSIS-29 were similar when completed by patients (physical scale: AUC = 0.79, 95% CI: 0.65 - 0.93 and 0.66, 95% CI: 0.48 - 0.84 for the psychological scale) and proxies (physical scale: 0.80, 95% CI: 0.72 - 0.96 and 0.71, 95% CI: 0.56 - 0.87 for the psychological scale)Conclusion: Although the results need to be further explored in larger samples, these results do point towards possible use of proxy respondents to assess patient perceived treatment change at the group level
- β¦